Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Last trade$279.06
Day change-$3.49 (-1.24%)
Day range$278.12 – $283.28
Volume2,952,933
Market cap$680.19B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$680.19B
Price / earnings
42.26×
Price / book
8.34×
Price / sales
6.85×
EV / sales
7.13×
EV / EBITDA
21.35×
Profitability
Earnings per share
$6.69
Return on assets
8.15%
Return on equity
19.74%
Dividend yield
1.87%
Liquidity and leverage
Debt / equity
0.55×
Current ratio
1.02×
Quick ratio
0.74×
Cash ratio
0.3×
Cash flow
Price / cash flow
26×
Price / free cash flow
33.66×
Free cash flow
$20.21B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JNJ, quarterly periods
Line item
Q3 FY2026 Sep 27, 2026
Q2 FY2026 Jun 28, 2026
Q1 FY2026 Mar 29, 2026
Q4 FY2025 Dec 28, 2025
Q3 FY2025 Sep 28, 2025
Q2 FY2025 Jun 29, 2025
Q1 FY2025 Mar 30, 2025
Q4 FY2024 Dec 29, 2024
Revenue
$25.4B
$25.31B
$24.06B
$24.56B
$23.99B
$23.74B
$21.89B
$22.52B
Cost of revenue
$8.1B
$8.05B
$8.11B
$7.97B
$7.3B
$7.63B
$7.36B
$7.13B
Gross profit
$17.3B
$17.26B
$15.96B
$16.6B
$16.69B
$16.12B
$14.54B
$15.39B
Selling, general and administrative
$6.29B
$6.43B
$6.03B
$6.75B
$5.92B
$5.89B
$5.11B
$6.45B
Research and development
$4.99B
$3.65B
$3.56B
$4.33B
$3.67B
$3.52B
$3.23B
$5.51B
Total operating expenses
$11.46B
$10.12B
$9.63B
$11.17B
$9.66B
$9.47B
$8.35B
$11.81B
Operating income
$5.85B
$7.14B
$6.33B
$5.43B
$7.03B
$6.65B
$6.18B
$3.58B
Interest expense
-$217M
-$281M
-$272M
-$214M
-$245M
-$308M
-$204M
-$137M
Income before taxes
$34M
$6.75B
$5.99B
$4.97B
$7.49B
$6.49B
$13.63B
$3.89B
Income taxes
-$176M
$1.21B
$755M
-$150M
$2.34B
$954M
$2.63B
$456M
Net income
$210M
$5.53B
$5.24B
$5.12B
$5.15B
$5.54B
$11B
$3.43B
Net income attributable to common shareholders
$210M
$5.53B
$5.24B
$5.12B
$5.15B
$5.54B
$11B
$3.43B
EBITDA
$8.14B
$9.13B
$8.36B
$7.52B
$8.87B
$8.65B
$7.97B
$5.33B
Basic earnings per share
$0.09
$2.30
$2.17
$2.12
$2.14
$2.30
$4.57
$1.43
Diluted earnings per share
$0.09
$2.27
$2.14
$2.09
$2.12
$2.29
$4.54
$1.41
Recent news
Company coverage with links to the original publishers.
AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.
Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.
Halozyme Therapeutics (HALO) has surged 43.1% over six months, outperforming the industry and S&P 500, driven by strong royalty revenues from its ENHANZE drug delivery technology partnerships. The company raised 2026 guidance with total revenues expected to reach $1.86-$1.925 billion and royalty revenues of $1.24-$1.26 billion. While recent acquisitions and proprietary product growth support long-term prospects, heavy reliance on partner companies for royalty income remains a key risk. Zacks rates the stock as a Hold.
Johnson & Johnson announced a definitive agreement to acquire clinical-stage biotech Ollin Biosciences for $2.2 billion, with potential milestone payments up to $1.12 billion. The acquisition adds OLN324, a phase III bispecific antibody for retinal vascular diseases, to J&J's ophthalmology portfolio. Blackstone Life Sciences will fund $750 million of phase III development in exchange for milestone payments and single-digit royalties. The deal is expected to close before end of 2026.
Johnson & Johnson demonstrates strong revenue growth with consistent quarter-over-quarter increases, while Novo Nordisk struggles with largely flat revenue despite a notable spike in Q1 2026. JNJ's diverse portfolio of 28+ billion-dollar products contrasts with Novo Nordisk's challenges as competitors catch up in the GLP-1 weight loss market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$1.34 per share
Declared
Oct 13, 2026
Ex-dividend
Nov 24, 2026
Pay date
Dec 8, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 25, 2026
$1.34
Sep 8, 2026
recurring
May 26, 2026
$1.34
Jun 9, 2026
recurring
Feb 24, 2026
$1.30
Mar 10, 2026
recurring
Nov 25, 2025
$1.30
Dec 9, 2025
recurring
Aug 26, 2025
$1.30
Sep 9, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.